48. Antibiotics against other bacteria:
Participants’ disclosures on the top three antibiotic classes that are most commonly prescribed to treat other bacteria, in hospitals or clinics. Options: aminocyclitols, aminoglycosides, carbapenems, cephalosporins, monobactams, penicillins, cyclic lipopeptides, folate antagonists, fluoroquinolones, glycopeptides, immunomodulators, ketolides, lincosamides, macrocyclics, macrolides, mycobacterials, nitrofurans, oxazolidinones, peptides, pleuromutilins, polypeptides, pyridopyrimidines, quinolones, streptogramins, sulphonamides, tetracycline, other
49. Treatment costs:
Participants’ disclosures on the average costs for antibiotics per patient, to treat bacterial infections in their hospital or clinic:
50. Single antibiotics or combinations:
Participants disclosures on the percentage (%) of their patients who are treated with one, two, three or more than three antibiotics at the same time (enhancers such as lactamase inhibitors are not included). Options1: one antibiotic, two antibiotics together, three antibiotics together, more then three antibiotics, other.
Innovation: In their own field, participants disclosures on what they believe to be the areas of greatest need in terms of innovation or change, to more effectively deal with and manage antibiotic resistance.
In their own field, participants disclosures on what they believe are the greatest barriers to more effectively dealing with or managing antibiotic resistance.
In their own field, participants opinions on what new initiatives government departments can promote, to more effectively deal with or manage antibiotic resistance.<
Copyright©2012 Vocus, Inc.
All rights reserved